Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)

Summary of Key Concepts

* Subcutaneous ICI products may offer significant time savings for patients, caregivers, and health care facilities with shorter compounding, administration, and chair time * With multiple ICI therapies now approved for subcutaneous injection and more under development, it is vital for institutions to develop interprofessional/multidisciplinary approaches and workflows to integrate novel therapies

Interprofessional, Multidisciplinary Collaboration Strategies for Novel Immune-Checkpoint Inhibitor Delivery Systems

* SC products offer convenient and safe options for patients that may be preferred by patients * Effective communication among interprofessional, multidisciplinary team and patients/caregivers is crucial to success and streamlining processes * Training is required for providers and staff related to operational, clinical, and financial considerations of SC products

Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)

* Atezolizumab and nivolumab are both FDA approved as SC products (pembrolizumab pending approval) * Overall safety and efficacy of SC ICI products are similar to IV ICI counterpart therapies * Patients receiving SC ICI may experience mild injection site reactions * Clinical guidelines (NCCN) recommend

Background of ICI & Highlights in Oncology

* Immune-checkpoint inhibitors (ICIs) represent a significant breakthrough in the field of cancer over the last 10-15 years * Multiple ICIs currently available as IV therapies (8 PD-1/PD-L1 agents approved since 2011 * Robust survival benefit seen with ICI across multiple tumor types * IV ICI therapy requires line access and creates increased chair time * Subcutaneous (SC) ICI options provide increased patient convenience and operational efficiencies * SC products may increase nurse resources due to time spent administering